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Cytotoxic T lymphocytes (CTL) and highly active antiretroviral therapy (HAART) are known to exert strong
evolutionary pressures on the virus population during human immunodeficiency virus (HIV) infection. How-
ever, it is not known whether CTL responses continue to substantially affect viral evolution during treatment.
To study the effect of immunologic pressure on viral sequences during HAART, we identified 10 targeted
HIV-specific CD8-T-cell epitopes in five treatment-naı¨ve patients, sequenced each epitope in plasma-derived
viruses, and then identified evidence of immunologic pressure at these epitopes by comparing the frequency of
viral variants in plasma to the frequency of the CD8-T-cell response for each variant identified. For one of
the five patients, evidence of viral evolution was found during therapy. The sequence of the CTL-targeted
epitope changed from an apparent escape variant prior to the initiation of therapy, to the sequence that is best
recognized by the CTL response after the initiation of therapy, and then finally to a new escape variant during
continued therapy. These data show that CTL-mediated pressure can continue to affect viral evolution after the
initiation of HAART, even when treatment drives the viral load below detectable levels, and suggest that
antiretroviral therapy may preferentially inhibit those virus variants that escape the CTL response.
In the two decades since AIDS was first described (14, 30),
it has become clear that human immunodeficiency virus
(HIV)-specific CD8 T lymphocytes play an important role in
the control of HIV replication. A temporal correlation exists
between the emergence of virus-specific CD8 T cells and the
initial control of viremia during primary infection (5, 26, 37). A
rapid expansion of clonal subsets containing HIV-specific cy-
totoxic T lymphocytes (CTL) also occurs during this time (38).
More recently, structured treatment interruption studies with
patients who were treated soon after infection showed that the
control of viremia is associated with an increase in the strength
and breadth of virus-specific CTL responses (44, 54). Viral
escape from immunologic containment after mutations affect-
ing the amino acid sequence of an immunodominant epitope
(15, 23, 29) and viral escape in response to infusions of large
numbers of monospecific cytotoxic T lymphocytes (25) also
suggest that HIV-specific CD8 T cells contribute to viral
control during chronic infection. In simian immunodeficiency
virus (SIV)-infected rhesus macaques, the depletion of CD8
T cells results in higher viral loads and a more rapid disease
progression (21, 48). Other rhesus macaque studies have dem-
onstrated predictable patterns of T-cell immune escape
through amino acid changes within cognate CD8 T-cell
epitopes (12) and a correlation between vaccine-elicited CD8
T-cell gamma interferon (IFN-) production and the control of
viremia after simian-human immunodeficiency virus challenge
(4).
Highly active antiretroviral therapy (HAART) has revolu-
tionized the treatment of AIDS. By lowering the viral load as
much as 5 log, HAART has increased longevity and allowed
the restoration of immune competency in HIV-infected sub-
jects (10, 11, 32, 52). Despite the potency of these drugs, viral
replication continues at low levels during antiretroviral therapy
(13, 18, 19, 42, 45). The decrease in viral load caused by
antiretroviral therapy also results in a rapid decrease in, but
not elimination of, HIV-specific CD8 T cells (2, 9, 34-36).
Viral quasispecies diversity and evolution are hallmarks of
HIV infection. Most evolution occurs in response to antiviral
pressures exerted by the immune response or by specific anti-
retroviral agents. Both the level of viral replication and the
degree of antiviral pressure affect the rate of viral quasispecies
evolution. In general, it is believed that HAART exerts more
antiviral pressure upon HIV than that exerted by the T-cell
immune response. In fact, antiretroviral therapy exerts such
potent antiviral pressure that antiretroviral resistance muta-
tions evolve even when viral replication is extremely low. It is
also known that during periods of high viral replication, when
CD8 T cells are likely the dominant antiviral pressure upon
the quasispecies, the CD8 T-cell pressure is sufficient to drive
escape within cognate epitopes (6, 41). What remains unclear
is whether CD8 T-cell pressure becomes insignificant com-
pared to the antiviral pressure of HAART during treatment.
Does this new pressure upon the quasispecies alter the balance
of viruses that do and do not escape CD8 T-cell recognition,
and is there sufficient residual pressure exerted by CD8 T
cells to drive the further evolution of escape variants within
cognate epitopes even when there is minimal viral replication?
To assess whether HIV-specific T cells continue to exert
evolutionary pressure on the virus during HAART, we as-
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sessed viral sequence evolution within cognate epitopes and
epitope-specific CD8 IFN- production both before and dur-
ing the first 20 weeks of HAART for five previously treatment-
naı¨ve subjects.
MATERIALS AND METHODS
Subjects. Five HIV-infected, antiretroviral treatment-naı¨ve subjects with ini-
tial CD4 T-cell counts of 200 cells/l were recruited for this study. All
subjects achieved viral loads of 400 copies/ml upon initiation of HAART and
maintained this level throughout the course of the study. HLA typing was
performed on all five subjects by a PCR sequence-specific primer methodology
(8). Subjects signed informed consent forms approved by the Institutional Re-
view Board of the University of Texas Southwestern Medical Center at Dallas.
Antibodies. Unconjugated mouse anti-human CD28, unconjugated mouse an-
ti-human CD49d, fluorescein isothiocyanate-conjugated mouse anti-human
IFN-, phycoerythrin-conjugated mouse anti-human CD3, peridinin chlorophyll
protein-conjugated mouse anti-human CD8, and allophycocyanin-conjugated
mouse anti-human CD69 monoclonal antibodies were obtained from Becton
Dickinson Immunocytometry Systems (BDIS) (San Jose, Calif.).
Cell preparation. Peripheral blood mononuclear cells (PBMC) were prepared
by standard Ficoll-Hypaque density gradient centrifugation (Pharmacia, Upp-
sala, Sweden). Both fresh and frozen PBMC were used for intracellular IFN-
staining. PBMC were frozen in heat-inactivated fetal calf serum containing 10%
dimethyl sulfoxide in a Forma CryoMed cell freezer (Marietta, Ohio). The cells
were stored at 140°C.
Peptides. Peptides were synthesized by Bio-Synthesis Inc. (Lewisville, Tex.)
and were 70% pure by high-performance liquid chromatography. The final
concentration of individual peptides in CD8 T-cell intracellular cytokine stain-
ing (ICS) assays was 2 g/ml unless otherwise noted. Screening and peptide
preparation were performed as described previously (9).
Cell stimulation. Cell stimulation was performed as described previously (24).
One million PBMC in 1 ml of R-10 medium (RPMI 1640 supplemented with
10% heat-inactivated fetal calf serum, 100 U of penicillin G/ml, 100 g of
streptomycin sulfate/ml, and 1.7 mM sodium glutamate) were incubated with 1
g each of costimulatory anti-CD28 and -CD49d monoclonal antibodies and 2
g of each peptide. Cells incubated with costimulatory antibodies only were
included in every experiment to control for the spontaneous production of
cytokines and the activation of cells prior to the addition of peptides. Cultures
were incubated at 37°C in a 5% CO2 incubator for 1 h, followed by an additional
5-h incubation in the presence of brefeldin A (10 g/ml; Sigma, St. Louis, Mo.).
PBMC that were used to compare the response to autologous peptides, deter-
mined by viral sequencing prior to the initiation of therapy, to the response to
optimized peptides were prepared within 16 weeks of the initiation of HAART.
Immunofluorescence staining. Peptide-stimulated and control cultures were
washed twice in cold Dulbecco’s phosphate-buffered saline containing 1% bovine
serum albumin and 0.1% sodium azide (fluorescence-activated cell sorting
[FACS] buffer) and then stained with directly conjugated anti-human CD3 and
anti-human CD8 antibodies for 30 min on ice. After a further wash, the cells
were resuspended in 750 l of a solution containing 50 l of enzyme-grade
Tween (Sigma) in 100 ml of 2 FACS-Lyse solution (BDIS) for 10 min in the
dark at room temperature. Permeabilized cells were immediately washed twice
with cold FACS buffer and spun down at 600  g for 8 min. The cell pellet was
resuspended in a minimal volume and stained with directly conjugated anti-
IFN- and anti-CD69 antibodies for 30 min at 4°C. After a final wash, the cells
were resuspended in Dulbecco’s phosphate-buffered saline containing 1% para-
formaldehyde (Electron Microscopy Systems, Fort Washington, Pa.) and stored
at 4°C until use.
Flow cytometric analysis. Six-parameter flow cytometric analysis was per-
formed with a FACSCalibur flow cytometer (BDIS). Between 50,000 and 130,000
events were acquired, gated on small lymphocytes, and assessed for CD3, CD8,
CD69, and IFN- expression. The results were analyzed with either PAINT-A-
GATE Plus (BDIS) or FlowJo (Tree Star Software, Ashland, Oreg.) software.
Autologous virus sequencing. HIV was concentrated from 8 to 11 ml of plasma
by centrifugation at 28,000  g for 1 h. The supernatant was removed, and the
viral pellet was extracted by use of a QIAmp viral RNA extraction kit (QIAGEN,
Valencia, Calif.). First-strand cDNA synthesis was performed with the outer
reverse primers shown in Table 1 by use of a SuperScript first-strand synthesis
system (Invitrogen, Carlsbad, Calif.). A two-step nested PCR amplification of the
first-strand cDNA was performed by the use of Platinum Taq polymerase Hi-
Fidelity kits (Invitrogen). The cycling parameters were as follows: activation at
94°C for 2 min followed by 30 cycles of 15 s of denaturation at 94°C, 30 s of
annealing at 54°C, and 30 s of extension at 68°C for both primary and secondary
amplification. Amplified DNAs were purified by gel electrophoresis, extracted by
use of a QIAquick gel extraction kit (QIAGEN), and ligated into the p-GEM
T-Easy vector system (Promega, Madison, Wis.). Plasmids were transformed into
competent DH5 Escherichia coli cells (Invitrogen). Individual clones were
picked by -complementation and then amplified by the use of Platinum Taq
polymerase Hi-Fidelity kits (Invitrogen) and M13 primers. Colony PCRs used a
2-min activation step at 94°C followed by 30 cycles of 30 s of denaturation at
94°C, 30 s of annealing at 57°C, and 3 min of extension at 72°C. Excess primers
were degraded by the incubation of 4 l of reaction product with 2 U each of
exonuclease I and shrimp alkaline phosphatase at 37°C for 1 h. Heating to 72°C
for 15 min terminated these reactions. The reaction products were sequenced on
an automated DNA sequencer (Applied Biosystems, Foster City, Calif.) by use
of an M13 forward or reverse primer.
At least 11 individual plasma-derived clones were sequenced at each region of
interest for each time point. The nucleotide sequence of each clone was com-
pared to those of all other clones isolated from the peripheral blood for that day
and subject. Each difference from the consensus sequence for that clone was
manually checked to ensure correct identification of the base sequence. Any base
sequence that was not identified at least twice within a specific epitope was
considered to be the result of polymerase infidelity and was disallowed, as
previously suggested (50). All PCR amplifications were performed with proce-
dural safeguards, including the division of all reagents into aliquots and the
physical separation of sample processing and post-PCR handling steps (27).
Control amplifications were performed by using first-strand DNA reaction mix-
tures to which no viral RNA was added. These reactions were carried through
the secondary PCR amplification step to ensure that there was no carryover
contamination.
Primers. Primers for gag, pol, nef, and env sequence amplification and first-
strand cDNA synthesis were designed based on the consensus B clade sequence
(51) and were synthesized by Sigma Genosys (Woodlands, Tex.) (Table 1). The
nucleotide-encoded regions sequenced with each primer set were as follows: p17,
Gag 4-149; p24, Gag 232-348; Pol, Pol 240-345; Env, Env 773-824 and Nef 1-60;
and Nef, Nef 36-161.
HLA-B51 stabilization studies. HLA-B51 stabilization experiments were per-
formed by a modification of the method of Hansen and Myers (17), using T2 (174
 CE.T2) cells (46) obtained from the American Type Culture Collection (Ma-
nassas, Va.). T2 cells were grown to log phase in R-10 and then washed three
times with RPMI 1640 supplemented with 100 U of penicillin G/ml, 100 g of
streptomycin sulfate/ml, and 1.7 mM sodium glutamate. Each incubation con-
TABLE 1. Primers used for amplification of viral sequences
Primers Forward sequence Reverse sequence
P17 primary AGAGCGTCAGTATTAAGCGGG CCCATGCATTTAAAGTTCTAGGTG
P17 secondary GGGAAAATTGGATAAATGGG CTAGGTGATATGGCCTGATGTAC
P24 primary AGATTGCATCCAGTGCATGC CCACATTTCCAACAGCCCTT
P24 secondary GGGAAGTGACATAGCAGGAACTACT ACATGCTGTCATCATTTCTTCTAGTGTA
Pol primary TTTGTACAGAAATGGAAAAGGAAGG AGGCTGTACTGTCCATTTATCAGGAT
Pol secondary CTCAAGACTTCTGGGAAGTTCAATT CAGATCCTACATACAAATCATCCATGTAT
Nef primary GGTGGGAGCAGCATCTCG TGCAGCTCTCGGGCCA
Nef secondary CCTGGGAAAACATGGAGCAA GTTGTTCTCTCCTTCATTGGCC
Env primary GAGGATTGTGGAACTTCTGGGAC CCCTGGTGTGTAGTTCTGCCA
Env secondary GGAGTCAGGAACTAAAGAATAGTGCTG TGCTTCTAGCCAGGCACAATC
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tained 500,000 cells in 1 ml of RPMI 1640 containing 10 g of 	2-microglobu-
lin/ml and between 0 and 100 g of peptide/ml. After 9 h of incubation at 37°C
in 5% CO2, the cells were washed and spun down at 300  g for 8 min in cold
FACS buffer. The supernatant was removed, and the pellet was resuspended in
a minimal volume and then stained for 30 min on ice with phycoerythrin-
conjugated anti-HLA-A,B,C (clone W6/32) obtained from Serotec (Raleigh,
N.C.). The cells were once again washed with FACS buffer and then were fixed
with 1% paraformaldehyde and stored at 4°C until analysis. Analyses were
performed with a FACSCalibur flow cytometer (BDIS).
RESULTS
Screening and initial sequencing. Responses to 1 to 3 of the
95 screening epitopes were found for each of the five subjects
studied (Table 2), as previously reported (9). Sequencing of
plasma viruses showed that there was a predominance of a
sequence that did not match that of the screening peptide in
three of the five subjects. In subjects B and F, a predominant
sequence of YPLTFGWCF was found rather than the se-
quence YPLTFGWCY(nef 135-143) used for screening (the vari-
ant residue is indicated in bold italics). In subject F, the viral
sequence IRLRPGGRK was found at the HLA-B27 epitope,
for which the peptide IRLRPGGKK(p17 19-27) was used for
screening, and two viral sequences, DIYKRWII and
EVYKRWII, were found at the HLA-B8 epitope, for which the
peptide EIYKRWII(p24 128-135) was used for screening. In sub-
ject R, two viral sequences, RLRPGGKKQ and RLRPGG
KKR, were found at the A3 epitope, for which the peptide
RLRPGGKKK(p17 20-28) was used for screening, and a single
viral sequence, TAFTIPST, was found at the HLA-B51
epitope, for which the peptide TAFTIPSI(pol 295-302) was used
for screening.
In patient F, the response to the peptide IRLRPGGK
K(p17 19-27), a B27 optimized epitope, was discordant with the
patient’s HLA type. This patient did not have a detectable
response to the overlapping HLA-A3-restricted optimized
epitopes RLRPGGKKK(p17 20-28), KIRLRPGGK(p17 18-26),
and RLRPGGKKKY(p17 20-29). Patient R (HLA type A31) re-
sponded to the HLA-A3-restricted epitope RLRPG
GKKK(p17 20-28) but had no detectable response to the other
overlapping optimized A3 epitopes in this region, i.e., KIRL
RPGGK(p17 18-26) and RLRPGGKKKY(p17 20-29).
Responses to autologous virus sequences. To determine if
autologous virus sequences could be recognized by CD8 T
cells from each subject, we ran parallel incubations containing
either a peptide representing the subject virus’s autologous
sequences or a peptide representing the optimized consensus
epitope. These assays were performed with frozen PBMC from
the closest date possible to the initiation of therapy. The fre-
quency of CD8 T cells producing IFN- in response to the
screening epitope and the autologous sequence were then
compared.
For subject B, the CD8 T-cell response to the screening
epitope YPLTFGWCY(nef 135-143) was 0.58% and the response
to the autologous viral sequence, YPLTFGWCF, was 0.95%.
For subject F, the frequency of response to YPLTFGWCY,
1.84%, was not significantly different from the 1.94% response
observed for the autologous virus sequence YPLTFGWCF.
For both subjects, only the YPLTFGWCF epitope sequence
was found in peripheral blood. For both subjects, assays of the
responses to YPLTFGWCY and YPLTFGWCF were done
with cells taken from the patients immediately prior to the
initiation of therapy. These results argue against viral escape at
these epitopes.
We next examined cognate CD8 T-cell epitopes at which
multiple autologous viral sequences were found. In all cases,
the least frequent viral sequence at the time of initiation of
treatment stimulated the largest CD8 T-cell population. Con-
versely, the most frequent viral epitope was the most poorly
recognized in terms of the total number of responding CD8
T cells. Specifically, in subject F, the dominant viral sequence
at epitope IRLRPGGKK(p17 19-27) was IRLRPGGRK, which
was found in 12 of 15 clones. The sequence coding for IRLR-
PGGKK was found in only 3 of 15 clones. The CD8 T-cell
response (0.75%) to the less frequent clone, IRLRPGGKK,
was more than twice the response to the more frequent se-
quence, IRLRPGGRK (0.33%), when measured 12 weeks af-
ter the initiation of therapy. Both of the sequences found at the
TABLE 2. HLA types, optimized epitopes used to screen for CD8 T-cell responses, and frequencies of epitope sequences found prior to the
initiation of therapy based on viral RNA sequencing





(no. of clones with sequence/
total no. of clones)
A A2, A2, B44, B70 SLYNTVATL(p17 77–85) A2 0.62 ––––––––– (20/20)
B A3, A31, B18, B39 YPLTFGWCY(nef 135–143) B7, B18, B35, B49, B53 0.58 ––––––––F (11/11)
F A1, A3, B8, B35 IRLRPGGKK(p17 19–27) B27
b 0.65 ––––––––– (3/15)
–––––––R– (12/15)
EIYKRWII(p24 128–135) B8 2.35 D––––––– (12/17)
–V–––––– (5/17)
YPLTFGWCY(nef 135–143) B7, B18, B35, B49, B53 1.84 ––––––––F (15/15)
G A2, A3, B7, B44 RLRPGGKKKY(p17 20–29) A3, A30, B42, Bw62 0.62
a
–––––––––– (18/18)
QVPLRPMTYK(nef 73–82) A3 0.37
a
–––––––––– (18/18)
R A2, A31, B51, B58w4 SLYNTVATL(p17 77–85) A2 0.15 ––––––––– (20/20)
RLRPGGKKK(p17 20–28) A3, A30, B42, Bw62 0.31 ––––––––– (6/20)
––––––––Q (11/20)
––––––––R (3/20)
TAFTIPSI(pol 295–302) B51 1.59 ––––––––T (24/24)
a Initial response determined at week 14 of therapy.
b Mismatch with patient’s HLA type.
c Dashes indicate identity with the optimized epitope sequence.
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HLA-B8 epitope EIYKRWII(p24 128-135), DIYKRWII and
EVYKRWII, were different from the peptide used to screen
for a response to this epitope. Of the autologous viral se-
quences found at this epitope, EVYKRWII was found in 5 of
17 clones and DIYKRWII was found in 12 of 17 clones. The
frequency of IFN- production by CD8 T cells incubated with
the less frequent sequence, EVYKRWII, was 3.69%, which was
twice that of CD8 T cells incubated with the more frequent
viral sequence, DIYKRWII (1.86%), when measured 16 weeks
after the initiation of therapy.
Sequencing of the epitope RLRPGGKKK(p17 20-28) in
plasma viruses from subject R identified sequences corre-
sponding to the screening peptide and two other sequences,
one in which the anchor position lysine was replaced with an
arginine (which has the same charge) (RLRPGGKKR) and
another in which the anchor position was replaced by an
amide-containing amino acid glutamine (RLRPGGKKQ).
Similar to the results for patient F, the production of IFN- in
response to the most frequently found variant, RLRPGGKKQ,
was less than that observed for the less common variant, RL
RPGGKKR, and the A3 optimized epitope RLRPGGKKK
when measured 14 weeks after the initiation of therapy. Of the
20 autologous viral sequences from subject R, 30% contained
the sequence RLRPGGKKK, 15% contained the sequence
RLRPGGKKR, and 55% contained the sequence RLRPG
GKKQ. The responses to RLRPGGKKK, RLRPGGKKR, and
RLRPGGKKQ were 0.09, 0.11, and 0.02%, respectively. For
subject R, all 24 clones sequenced for the HLA-B51 epitope
TAFTIPSI(Pol 295-302) showed the previously described HLA-
B51 escape variant TAFTIPST (49). Again, the frequency of
response to the less frequent viral sequence, TAFTIPSI
(0.45%), was higher than that to the more frequent viral se-
quence, TAFTIPST (0.31%), when measured 14 weeks after
the initiation of therapy.
Longitudinal virus sequencing at sites of CD8 T-cell pres-
sure. We sequenced plasma viruses from three patients (sub-
jects B, F, and R) at six targeted epitopes multiple times after
the initiation of therapy. At four of these epitopes, there was
evidence of viral evolution, as shown by multiple viral se-
quences within the targeted epitopes, a larger response to the
least common sequence, and a lesser response to the most
frequently observed sequence. There was no evidence of viral
evolution at the other two epitopes. It is known that antiret-
roviral therapy causes dramatic changes in both the viral load
and HIV-specific T cells (2, 9, 34–36). Due to the very low
plasma virus loads after the initiation of therapy, not all re-
gions of the plasma virus were successfully amplified and se-
quenced at each time point. Viral sequences were monitored
for 12 to 44 weeks after the initiation of therapy (Tables 3, 4,
and 5).
For subjects B and F, there was no evidence of immune
pressure on the Nef135-143 epitope before the initiation of ther-
apy and no changes in the autologous plasma virus sequence
within this epitope during the first 28 and 44 weeks of therapy
(Table 3). Similarly, for epitopes p1719-27 and p24259-267 in
subject F, no substantial changes in the viral quasispecies
within these targeted epitopes were found during the first 20
weeks of treatment (Table 4). For patient F, it was possible to
evaluate the response to variant peptide epitopes in CD8 T
cells that were present either concurrently or within 1 month of
the viral quasispecies sequencing (Fig. 1). Once again, the most
frequently seen viral sequences at the optimized epitopes IRL
RPGGKK(p17 19-27) and EIYKRWII(p24 128-135) were those
which stimulated the smallest specific CD8-T-cell response.
This was not unexpected since no dramatic changes in se-
quence frequency were seen after the initiation of therapy.
A different pattern was observed for subject R. The majority
of the autologous plasma virus sequences found for epitope
p1720-28 prior to the initiation of therapy encoded the peptide
RLRPGGKKQ, which was different from the screening pep-
tide RLRPGGKKK (Table 5). At week 14 of antiretroviral
therapy, there was a major change in the viral quasispecies
such that the plasma virus sequences present were either RL
RPGGKKK (14 of 16 clones) or RLRPGGKKR (2 of 16
clones), both of which were epitopes that were well recognized
by HIV-specific CD8 T cells. By week 19, the viral quasispe-
cies had reverted back to the sequence RLRPGGKKQ, which
was not well recognized.
Similarly, prior to the initiation of therapy, only the se-
quence TAFTIPST was seen at the Pol295-302 epitope (Table
5). After 14 weeks of treatment, this viral sequence was com-
pletely replaced within the plasma virus compartment by vi-
ruses that contained the sequence TAFTIPSI at this site. This
sequence was not seen in this subject prior to antiretroviral
therapy. By week 19 of therapy, the quasispecies was again
replaced, this time by viruses that all had the sequence TAF
TIPSM at the Pol295-302 epitope. The nucleotide sequences
responsible for the changes in amino acid sequences from
TAFTIPST to TAFTIPSI to TAFTIPSM suggest a stepwise
progression. Prior to HAART, the original codon for the C-
terminal threonine in this epitope was ACA (24 of 24 clones).
At week 14, a single C-to-T change in this codon (ACA to
ATA) was responsible for a change to isoleucine at the C
terminus of the epitope (14 of 14 clones). At week 19, a further
single nucleotide change in this codon (ATA to ATG) was
responsible for a change to methionine at the C terminus (18
TABLE 3. Frequencies of optimized epitope YPLTFGWCY(nef 135–143)
and of variant epitope before and after the initiation of therapy in














0 245,000 0/10 10/10
8 ND 0/14 14/14
20 563 0/18 18/18
28  400 0/17 17/17
36  400 0/19 19/19
44  400 0/14 14/14
F
0 23,620 0/15 15/15
12 ND 0/16 16/16
16 400
20 ND 0/16 16/16
24 400
28 ND 0/15 15/15
32 400
a ND, not determined.
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of 18 clones). In PBMC collected 19 weeks after the initiation
of therapy, when TAFTIPSM was the only viral sequence
found, the frequency of a response to TAFTIPSM, 0.63%, was
only slightly less than that to TAFTIPSI (0.73%). The response
to TAFTIPST was 0.55%. No evidence of a significant change
in the relative response to TAFTIPSI versus that to TAFTIPST
at weeks 12 and 19 or a change in the relative response to
TAFTIPSI versus that to TAFTIPSM at weeks 19 and 25 could
be seen (Fig. 2).
Evidence for CD8 T-cell escape at Pol295-302. In a popula-
tion-based study, Moore et al. (33) reported that substitution
of the consensus sequence isoleucine at position 135 of the
B51-restricted epitope TAFTIPSI occurred in 39 of 40 HLA
B51 individuals compared to 127 of 431 non-HLA-B51 indi-
viduals. This HLA-dependent substitution of isoleucine in this
epitope suggests that substitution of a dissimilar amino acid at
the B51 anchor point may affect the ability of variant peptides
to bind to HLA-B51. Although fewer CD8 T cells produced
IFN- when stimulated with TAFTIPST or TAFTIPSM than
when stimulated with TAFTIPSI, the differences observed
were small. Despite the modest differences in IFN- produc-
tion, CD8 T cells showed marked differences in the down-
regulation of CD3 when incubated with TAFTIPST or TAF
TIPSM compared to that observed with TAFTIPSI (Fig. 3a).
The mean geometric CD3 fluorescence intensity in the non-
stimulated CD8-T-cell population was 160 to 165 in these
assays. In comparison, the mean CD3 fluorescence intensities
were 24.8 in CD8 T cells responding to TAFTIPSI, 57.9 in
CD8 T cells responding to TAFTIPSM, and 87.8 in CD8 T
cells responding to TAFTIPST. A similar, although less
marked pattern, was seen with CD8 staining (Fig. 3b). These
data suggest that fewer T-cell receptors are triggered by the
formation of the TCR/pMHCI complex when TAFTIPSM and
TAFTIPST are incubated with PBMC than when TAFTIPSI is
used at a concentration of 2 g/ml (53).
To define differential recognition in more detail, we mea-
sured ex vivo IFN- production in response to both TAFTIPSI
and TAFTIPST over a range of peptide concentrations. As
shown in Fig. 4a, a 50% maximal response to TAFTIPST
required a sixfold higher concentration of peptide (90 nM)
than that required for TAFTIPSI (15 nM), clearly demonstrat-
ing the fact that TAFTIPST was less well recognized by the
HIV-specific CD8 T cells of subject R. A similar titration
curve showed decreased responses to TAFTIPSM at 23 nM,
230 nM, and 2.3 M compared to the responses to TAFTIPSI
(Fig. 4b). The limited number of cells did not allow an estima-
tion of a half-saturation point for TAFTIPSM.
HLA class I stabilization studies were performed with 174 
CEM.T2 (T2) cells to investigate the binding of TAFTIPSI,
TAFTIPST, and TAFTIPSM to HLA-B51 (Fig. 5). The cyto-
megalovirus pp65 HLA-A2 immunodominant peptide NLVP
MVATV (acting as a positive control), the HLA-B51 epitope
TAFTIPSI, the variants TAFTIPST and TAFTIPSM, and the
HLA-B27 epitope IRLRPGGKK (acting as a negative control)
were tested for the ability to stabilize HLA-A2 and -B51 mol-
ecules. Incubations with TAFTIPSI and NLVPMVATV
showed the most HLA class I stabilization, as measured by the
surface staining of HLA with an anti-HLA-A,B,C monoclonal
antibody (W6/32). The HLA stabilization level with TAFT
IPST and TAFTIPSM was lower than that observed with TAF
TABLE 4. Frequencies of optimized epitope and variant epitope sequences in subject F before and after initiation of therapy for epitopes
IRLRPGGKK(p17 19–27) and EIYKRWII(p24 128–135) based on viral RNA sequencing
Time (wks)
in therapy Viral load
a
Sequence (no. of clones/total)
IRLRPGGKK EIYKRWII
0 19,627 IRLRPGGKK (3/15), –––––––R– (12/15) EIYKRWII (0/17), D––––––– (12/17), –V–––––– (5/17)
4 ND IRLRPGGKK (6/19), –––––––R– (13/19) EIYKRWII (0/22), D––––––– (22/22), –V–––––– (0/22)
12 400 IRLRPGGKK (6/14), –––––––R– (8/14) EIYKRWII (0/14), D––––––– (14/14), –V–––––– (0/14)
16 ND IRLRPGGKK (8/17), –––––––R– (9/17)
20 ND IRLRPGGKK (0/17), –––––––R– (17/17)
24 400
a ND, not determined.
TABLE 5. Frequencies of optimized epitope and variant epitope sequences in subject R before and after initiation of therapy for epitopes
RLRPGGKKK(p17 20–28) and TAFTIPSI(pol 295–302) based on viral RNA sequencing
Time (wks)
in therapy Viral load
Sequence (no. of clones/total)
RLRPGGKKK TAFTIPSI
0 98,597 RLRPGGKKK (6/20) TAFTIPSI (0/24)
––––––––Q (11/20) –––––––T (24/24)
––––––––R (3/20) –––––––M (0/24)
9.5 478
14 NDa RLRPGGKKK (14/16) TAFTIPSI (14/14)
––––––––Q (0/16) –––––––T (0/14)
––––––––R (2/16) –––––––M (0/14)
19 400 RLRPGGKKK (0/15) TAFTIPSI (0/18)
––––––––Q (15/15) –––––––T (0/18)
––––––––R (0/15) –––––––M (18/18)
a ND, not determined.
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TIPSI and NLVPMVATV but higher than that observed with
the HLA-B27 epitope IRLRPGGKK.
These data explain the similarities in the production of
IFN- in response to stimulation by 2-g/ml TAFTIPSI, TAF
TIPST, and TAFTIPSM despite the substitution of a polar
-CHOHCH3 group in the case of TAFTIPST and a
-C2H4SCH3 group in the case of TAFTIPSM for the
-CH(CH3)C2H5 group of TAFTIPSI. At saturating concentra-
tions of peptide, the effects of the differences in binding avidity
for TAFTIPSI, TAFTIPST, and TAFTIPSM were minimized.
This masked the effects of substitutions of threonine and me-
thionine for isoleucine at the carboxy-terminal anchor residue.
Lack of nucleoside reverse transcriptase resistance muta-
tions. The primers used to sequence the pol gene allowed the
sequencing of amino acids 241 to 347 (HXB2 sequence), which
correspond to amino acids 86 to 191 of reverse transcriptase
(Fig. 6). In this 105-amino-acid sequence, the only point where
the sequence changed over the 19 weeks of therapy in subject
R was at the terminal anchor position for the epitope TAFT
IPSI. Subject R’s treatment regimen included combivir
(zidovudine and lamivudine) and nevirapine. No evidence of
drug resistance mutations for either lamivudine or nevirapine
was found during this period. While not all potential sites
corresponding to zidovudine resistance were sequenced, there
was no evidence of a resistance mutation to zidovudine found
at the V118 position. In addition, prior to the initiation of
therapy, eight plasma virus clones were sequenced, and there
was no evidence of zidovudine resistance mutations (M41L,
E44D, D67N, or K70R) or multinucleoside reverse transcrip-
tase complex mutations (A62V or the 69 insertion complex)
(data not shown).
Lack of response to autologous peptides at other HLA
matched epitopes. To assess whether screening with peptide
epitopes that differed from the autologous virus sequences led
to a failure to detect specific responses, we sequenced plasma
FIG. 1. Epitope-specific CD8 T-cell responses and autologous virus sequences from subject F. CD8 T-cell responses to screening peptides
and peptide variants are shown to the left in each graph. Epitope frequencies, determined by nucleic acid sequencing of viral clones, are shown
to the right in each graph. Screening peptides and variant amino acid sequences are shown on the abscissa. None of the sequenced clones contained
the screening peptide EIYKRWII. Sequencing data and response data for the epitope IRLRPGGKK and its variant are from week 12 of therapy.
Sequencing data are from 12 weeks and response data are from week 16 of therapy for EIYKRWII and its variants. An asterisk indicates that no
nucleotide sequence corresponding to the screening epitope EIYKRWII was found in any viral sequence determined either prior to or after the
initiation of therapy.
FIG. 2. Plot of viral load and CD8 IFN- production in response
to TAFTIPSI, TAFTIPST, and TAFTIPSM in patient R. CD8-T-cell
responses to individual peptides and viral loads are plotted against the
time after the initiation of treatment. Responses to either TAFTIPSI,
TAFTIPST, or TAFTIPSM were measured at the same time. The
arrows and text indicate the numbers of viral clones sequenced and the
sequence found at Pol 295–302 at the indicated times. The peptide
concentration in all assays was 2 g/ml.
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viral RNAs from subject B that had been collected prior to the
initiation of therapy at the five regions for which we had PCR
primers (Table 1). These regions corresponded to amino acids
in p17 (4-149), p24 (232-348), Pol (240-345), Env (773-824),
and Nef (1-161), or approximately 10% of the total HIV ge-
nome. Based on the HLA type of subject B, eight potential
epitopes were identified for this subject. Seven variant se-
quences were found at those sites (Table 6). Each of these
peptides was synthesized and used to assay CD8 T-cell re-
sponses. As with the peptides used for the initial screen, no
response was found to any of the variant peptides for this
subject (data not shown). Therefore, it is unlikely that the use
of nonautologous virus sequences in this subject affected our
ability to detect epitope-specific CD8 T cells.
FIG. 3. Contour plots showing peptide-specific CD3 and CD8 down-regulation in CD8 T cells from patient R in response to TAFTIPSI and
other autologous viral epitopes 19 weeks after the initiation of HAART. PBMC were gated sequentially on small lymphocytes (a) and on small
lymphocytes and CD3 expression (b). Plots show CD3 or CD8 surface staining versus intracellular IFN- staining. Cells were incubated in the
absence or presence of added peptide, as indicated. The peptide concentration was 2 g/ml throughout. The geometric mean fluorescence for CD3
or CD8 expression in responding CD8 T cells is given in the lower right corner of each contour plot.
FIG. 4. Plot of data showing frequency of CD8-T-cell IFN- production in response to various concentrations of TAFTIPSI, TAFTIPST, and
TAFTIPSM. Plot a shows a sigmoidal fit of CD8 IFN- production in response to various concentrations of TAFTIPSI (E) and TAFTIPST (F).
The half-saturation point for TAFTIPSI was 15 nM and that for TAFTIPST was 90 nM. Responses shown are from PBMC prepared from blood
drawn during week 14 of treatment. Plot b shows CD8 IFN- production in response to various concentrations of TAFTIPSI (E) and TAFTIPSM
(F). Responses shown are from blood drawn during week 25 of treatment.
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DISCUSSION
The initiation of HAART dramatically reduces the antigenic
load and results in a rapid decrease in HIV-specific CD8 T
cells (2, 9, 34–36). During effective therapy, the viral load is
reduced to such a low level that the progression of drug resis-
tance appears to almost stop, even though low-level viral rep-
lication continues. For this setting, it was not known if immu-
nologic pressure continues to drive viral evolution. In this
study, we showed evidence of continued evolution in a recently
infected individual during the first 19 weeks of therapy, even
when the viral load was 400 copies/ml.
In our cohort of five patients, we found evidence of CD8-
T-cell-dependent antiviral pressure in two HIV-infected sub-
jects. For patient F, evidence of CTL-driven viral evolution was
found at the HLA-B27 optimized epitope IRLRPGGK
K(P17 19-27) and the HLA-B8 epitope EIYKRWII(P24 259-267).
For patient R, evidence of CTL-driven viral evolution was
found at the HLA-B51 epitope TAFTIPSI(Pol 295-302) and the
HLA-A3 epitope RLRPGGKKK(P17 20-28). The appearance of
a new variant at the targeted epitope TAFTIPSI(Pol 295-302) at
week 19 in patient R represents evidence of CTL-driven evo-
lution during antiretroviral therapy. Unlike the data for patient
R for the targeted epitope RLRPGGKKK(p17 20-28), at which
the recurrence of RLRPGGKKQ in all 15 clones sequenced at
week 19 of treatment may represent either continued evolution
during therapy or amplification of a single viral clone due to
sampling variability at low levels of starting template, TAFT
IPSM was not found before therapy was initiated and therefore
represents further viral evolution at this epitope.
Subject R was a recent seroconverter when HAART was
initiated. Subject F had been infected for at least a year and a
half, and patient B had been infected for at least 10 months
prior to the initiation of therapy. Since viral sequences were
monitored longitudinally for only three patients, the fact that
evidence of viral evolution was observed only in the recent
seroconverter might not be significant; however, viral evolution
does occur rapidly soon after infection (6, 41). Viral replication
rates are highest before CTL responses develop, and viruses
exposed to the immune system immediately after infection
represent a “clean slate” against which the developing re-
sponses can drive viral evolution. This, coupled with a CTL
response focused on a smaller number of epitopes in acute
HIV (54), may explain the relatively rapid changes in viral
sequence at Pol 295-302 in patient R compared to those in
patients B and F, who were chronically infected at the time of
initiation of therapy (31).
These data do not explain the reason for the appearance of
the optimized epitope TAFTIPSI 14 weeks after the initiation
of therapy. Rapid shifts in different viral quasispecies due to
preferential suppression of the most replication-capable (CTL
escape) variant, the emergence of a previously suppressed qua-
sispecies due to the decrease in HIV-specific CD8 T cells, or
the emergence of different quasispecies from different reser-
voirs during the initiation of therapy are all possible explana-
tions (39, 40). The emergence of TAFTIPSM at week 19 oc-
curred under somewhat different circumstances. Decreases in
viral load do not occur as rapidly during the second phase of
viral decay during HAART (39). As a result, dramatic shifts in
viral populations are less likely to result in the appearance of
FIG. 5. Peptide-induced surface expression of HLA-A2 and -B51
in T2 cells. T2 cells were incubated for 9 h in RPMI supplemented with
100 U of penicillin/ml, 100 g of streptomycin sulfate/ml, 1.7 mM
sodium glutamate, and 10 g of 	2-microglobulin/ml, exposed to
NLVPVATV, TAFTIPSI, TAFTIPST, TAFTIPSM, and IRLRPG
GKK at the indicated concentrations, and then stained with anti-HLA-
A,B,C (W6/32). Results are shown as mean geometric fluorescence
intensities versus peptide concentrations.
FIG. 6. Clade B consensus sequence and consensus sequences for
plasma viruses from weeks 0, 14, and 19 of HAART for subject R.
Twenty-four, 16, and 18 plasmids containing amplified viral cDNAs
were sequenced, respectively. Dots indicate identity with the clade B
consensus sequence. The locations of common drug resistance muta-
tions for zidovudine (V118I), lamivudine (M184V), and nevirapine
(K103N, Y181C/I, and Y188C/L/H) are circled in the consensus B
clade sequence.
TABLE 6. Presence of variant sequences at HLA matched
optimized epitopes in HIV isolated from blood of patient B









a Variant residues are indicated in bold italics.
3660 CASAZZA ET AL. J. VIROL.
minor quasispecies. It is also unlikely that the presence of
TAFTIPSM, a rarer sequence than TAFTIPST, would be due
to a preexisting sequence in a recently infected individual,
especially as this sequence was not detected prior to the initi-
ation of HAART. This, coupled with the stepwise change in
nucleotide sequence observed in the transition from TAFT
IPST to TAFTIPSI to TAFTIPSM, suggests that the emer-
gence of TAFTIPSM represents a new variant.
Any mutation in the reverse transcriptase gene carries the
possibility of effecting antiretroviral drug resistance. No evi-
dence of a clinically significant drug resistance mutation was
seen in patient R either by the criteria of the Drug Resistance
Mutations Group of the International AIDS Society—USA
(22) or from clinical data. Patient R has maintained an unde-
tectable viral load for 4 years on the same treatment regi-
men. Nonetheless, Brown et al. (7) have suggested that both
TAFTIPST and TAFTIPSM may decrease the sensitivity to
nonnucleoside reverse transcriptase inhibitors (NNRTIs).
These authors screened 110 patients who had moderate reduc-
tions in sensitivity to NNRTIs. Twenty-seven of these individ-
uals had an I135T mutation. Only one patient had an I135M
mutation. In this patient, the I135M mutation occurred in
combination with an E138A mutation, a site where mutations
are known to affect the sensitivity to NNRTIs (47). Resistance
test vectors using the consensus reverse transcriptase sequence
with either an I-to-T or I-to-M mutation at amino acid 135 of
the reverse transcriptase gave a 2- or 2.6-fold change in resis-
tance, respectively. A review of the Stanford HIV Drug Data-
base (43) showed 10 patients with an I135M mutation and no
major nevirapine resistance mutations based on sequencing
results. Resistance test vectors for these 10 patients showed a
median change in sensitivity of 1.3. These data suggest that an
I135M mutation has a minimal or undetectable effect on drug
sensitivity in patients with nonconsensus RT sequences.
Two recent papers have assessed the HIV-specific CD8
T-cell response based on autologous viral sequences rather
than consensus sequences. Lee et al. (28) suggested that the
response to autologous sequences was lower than that ob-
served with sequences closely related to the consensus B clade
sequence. Altfeld et al. (3) suggested the opposite, i.e., that
responses to autologous sequences occurred with a higher fre-
quency than those to consensus sequences. With individual
epitopes, we found both situations. However, our data also
demonstrated the difficulty with using saturating peptide con-
centrations in ex vivo assays to determine the physiologic sig-
nificance of a change in sequence at any epitope. Despite the
relatively small difference in the responses to TAFTIPSI, TAF
TIPSM, and TAFTIPST at 2 g of peptide/ml, three lines of
evidence suggest that TAFTIPST and TAFTIPSM are escape
variants. First, the down-regulation of CD3 expression was
larger in response to the optimized epitope TAFTIPSI than it
was for either of the variant peptides (TAFTIPSM and TAF
TIPST). Second, titration experiments showed decreased re-
sponses to TAFTIPST and TAFTIPSM compared to those to
TAFTIPSI. Third, HLA stabilization experiments showed a
weaker binding of TAFTIPST and TAFTIPSM to HLA-B51
than that observed with the optimized epitope TAFTIPSI.
These data, in combination with the viral sequencing data
presented, indicate that TAFTIPST and TAFTIPSM represent
escape variants in subject R. Such a conclusion would be hard
to make based on an isolated test. Our data show that using
peptides at saturating concentrations increases the ability of
assays to identify responses to variants that differ from the
consensus sequence. Therefore, the best use of screening as-
says with overlapping peptides based on consensus sequences
may be to identify epitopes to which CD8 T cells are directed
in vivo rather than to quantify these responses accurately. Our
failure to find any additional responses when eight peptides
using autologous sequences were substituted for consensus
optimized epitope sequences suggests that the consensus-
based approach does identify most epitopes to which HIV-
specific CD8 T cells are directed (Table 6).
A recent paper by Allen et al. (1) may explain the absence of
a response to the frequently recognized A3 epitopes KIRLR
PGGKK(p17 19-27) and RLRPGGKKK(p17 20-28) in patient F.
Allen et al. (1) showed that a K28Q mutation results in an
eightfold increase in the 50% inhibitory concentration for
binding of this variant to the HLA-A3 molecule and also in-
terferes with proteasome processing of the overlapping A3
epitope KIRLRPGGKK(p17 19-27). At each of the five time
points observed and in 82 viral sequences, a K28Q mutation
was found in the viruses sequenced from patient F (data not
shown), suggesting that the K28Q mutation may be responsible
for the absence of these common A3 responses.
Evidence of viral evolution at targeted CTL epitopes during
effective antiretroviral treatment suggests that therapeutic vac-
cination of recently infected individuals may be more success-
ful than structured treatment interruptions. The development
of escape variants occurs rapidly in the first months after in-
fection (6, 41). It is therefore important to limit viral evolution
as quickly as possible in those who were recently infected.
Structured treatment interruption does appear to enhance the
immunologic control of viral replication under some circum-
stances (44), but as shown here, conditions exist long after the
initiation of treatment that allow the outgrowth of quasispecies
containing escape variants. Therapeutic vaccination might
limit this possibility by decreasing the opportunity for further
viral evolution, although even with prolonged HAART, this
may not be absolute (16, 20, 55).
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